<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Tob Induc Dis</journal-id>
<journal-id journal-id-type="iso-abbrev">Tob Induc Dis</journal-id>
<journal-id journal-id-type="publisher-id">TID</journal-id>
<journal-title-group>
<journal-title>Tobacco Induced Diseases</journal-title>
</journal-title-group>
<issn pub-type="ppub">2070-7266</issn>
<issn pub-type="epub">1617-9625</issn>
<publisher>
<publisher-name>European Publishing on behalf of the International Society for the Prevention of Tobacco Induced Diseases (ISPTID)</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32547353</article-id>
<article-id pub-id-type="pmc">7291960</article-id>
<article-id pub-id-type="publisher-id">50</article-id>
<article-id pub-id-type="doi">10.18332/tid/122465</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cytochrome P450 2A6 whole-gene deletion (CYP2A6*4) polymorphism reduces risk of lung cancer: A meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Johani</surname>
<given-names>Fadzrul H.</given-names>
</name>
<xref ref-type="aff" rid="aff0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Majid</surname>
<given-names>Mohd S. A.</given-names>
</name>
<xref ref-type="aff" rid="aff0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Azme</surname>
<given-names>Muhammad H.</given-names>
</name>
<xref ref-type="aff" rid="aff0001">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Nawi</surname>
<given-names>Azmawati M.</given-names>
</name>
<xref ref-type="aff" rid="aff0001">1</xref>
</contrib>
<aff id="aff0001"><label>1</label>Department of Community Health, Faculty of Medicine, University Kebangsaan Malaysia, Cheras, Malaysia</aff>
</contrib-group>
<author-notes>
<corresp id="cor1"><bold>CORRESPONDENCE TO</bold> Azmawati M. Nawi. Department of Community Health, Faculty of Medicine, University Kebangsaan Malaysia, Jln Yaacob Latif, Bdr Tun Razak, 56000, Cheras, Kuala Lumpur, Malaysia. E-mail: <email xlink:href="azmawati@ppukm.ukm.edu.my">azmawati@ppukm.ukm.edu.my</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>02</day>
<month>6</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>18</volume>
<elocation-id>50</elocation-id>
<history>
<date date-type="received">
<day>30</day>
<month>12</month>
<year>2019</year>
</date>
<date date-type="rev-recd">
<day>15</day>
<month>5</month>
<year>2020</year>
</date>
<date date-type="accepted">
<day>15</day>
<month>5</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© 2020 Johani F.H. et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License.</license-p>
</license>
</permissions>
<abstract>
<sec id="s1">
<title>INTRODUCTION</title>
<p>Lung cancer is the most commonly diagnosed cancer worldwide and is the leading cause of cancer death. Smoking is a major contributor to the pathogenesis of lung cancer. Cytochrome P450 2A6 (<italic>CYP2A6</italic>) is responsible for the metabolic activation of most tobacco carcinogens. <italic>CYP2A6</italic> genetic polymorphism can cause variations in the human metabolism of xenobiotics. We performed this meta-analysis to determine the association between whole-gene <italic>CYP2A6</italic> deletion polymorphism (<italic>CYP2A6*4</italic>) and lung cancer risk.</p>
</sec>
<sec id="s2">
<title>METHODS</title>
<p>The PubMed, SAGE, Science Direct, the Cochrane Library and Ovid databases were searched for observational studies before October 2018. Methodological quality was assessed using the Newcastle-Ottawa Quality Assessment Scale (NOS).</p>
</sec>
<sec id="s3">
<title>RESULTS</title>
<p>Nine case-control studies involving 4385 lung cancer cases and 4142 controls were included in the analysis. The random-effects model was used to combine results from individual studies. The pooled odds ratio was 0.39 (95% CI: 0.27–0.56). There was no heterogeneity across studies (χ<sup>2</sup>=2.49, p=0.96, I<sup>2</sup>=0%).</p>
</sec>
<sec id="s4">
<title>CONCLUSIONS</title>
<p>Current evidence from the case-control studies suggests that the <italic>CYP2A6</italic> whole-gene deletion polymorphism decreases the risk of lung cancer. Further research is needed to identify any potential confounding factors that may impact this association.</p>
</sec>
</abstract>
<kwd-group>
<kwd>CYP2A6*4</kwd>
<kwd>Cytochrome P450 2A6</kwd>
<kwd>lung cancer</kwd>
<kwd>meta-analysis</kwd>
<kwd>polymorphism</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1" sec-type="intro">
<title>INTRODUCTION</title>
<p>In 2018, there were an estimated 18.1 million new cancer cases and 9.6 million cancer deaths, worldwide. Lung cancer is the most commonly diagnosed cancer worldwide, constituting 11.6% of total cancer cases, and is the leading cause of cancer death (18.4% of total cancer deaths)<sup><xref ref-type="bibr" rid="cit0001">1</xref></sup>.</p>
<p>Smoking is a major contributor to the pathogenesis of lung cancer<sup><xref ref-type="bibr" rid="cit0002">2</xref></sup>. Even exposure to secondhand tobacco smoke increases the risk of developing lung cancer among non-smokers<sup><xref ref-type="bibr" rid="cit0003">3</xref>,<xref ref-type="bibr" rid="cit0004">4</xref></sup>. The pro-carcinogens specific to tobacco are clearly implicated in the progression of lung malignancies<sup><xref ref-type="bibr" rid="cit0005">5</xref>,<xref ref-type="bibr" rid="cit0006">6</xref></sup>. However, not all smokers will eventually develop lung cancer in their lifetime. These individual differences in lung cancer morbidity could be due to other determinants such as genetic susceptibility<sup><xref ref-type="bibr" rid="cit0007">7</xref>,<xref ref-type="bibr" rid="cit0008">8</xref></sup> and environmental factors<sup><xref ref-type="bibr" rid="cit0009">9</xref>-<xref ref-type="bibr" rid="cit0011">11</xref></sup>. Thus, it is important to identify the genetic variants that influence the risk of lung cancer initiation<sup><xref ref-type="bibr" rid="cit0012">12</xref>,<xref ref-type="bibr" rid="cit0013">13</xref></sup>.</p>
<p>Most tobacco carcinogens require metabolic activation, which is mainly executed by the cytochrome P450 (CYP) enzymes<sup><xref ref-type="bibr" rid="cit0014">14</xref></sup>. Electrophile agents with short lifespans (which are produced in metabolic activation) cross-react with DNA, causing DNA damage and initiating tumours<sup><xref ref-type="bibr" rid="cit0015">15</xref>,<xref ref-type="bibr" rid="cit0016">16</xref></sup>. Among the CYP isozymes, CYP family 2 subfamily A member 6 (<italic>CYP2A6</italic>) is responsible for nicotine metabolism and for the metabolic activation of the tobacco-specific pro-carcinogens <italic>N</italic>-nitrosamine <italic>N</italic>-nitrosonornicotine (NNN) and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK), which can eventually contribute to the progression of lung cancer<sup><xref ref-type="bibr" rid="cit0005">5</xref></sup>.</p>
<p>Genetic polymorphism is defined as the inheritance of a trait controlled by a single genetic locus with two alleles in which the least common allele has a frequency of approximately ≥1% that can cause variation in the DNA sequence in individuals, groups, or populations<sup><xref ref-type="bibr" rid="cit0017">17</xref></sup>. The difference in DNA sequence may not alter the overall product sufficiently enough to produce a different protein but may affect the specific activity of the enzyme, and binding efficiencies such as those for transcription factors or membrane proteins, or other features and function<sup><xref ref-type="bibr" rid="cit0018">18</xref></sup>. Thus, Cytochrome P450 2A6 (<italic>CYP2A6</italic>) polymorphism can influence how humans metabolize xenobiotics.</p>
<p>Over the past two decades, several studies have assessed the association between <italic>CYP2A6</italic> polymorphism, including whole-gene deletion of <italic>CYP2A6</italic> on allele 4 (<italic>CYP2A6*4</italic>), and the risk of lung cancer among different ethnic populations, but the results have been inconsistent<sup><xref ref-type="bibr" rid="cit0012">12</xref>,<xref ref-type="bibr" rid="cit0019">19</xref>,<xref ref-type="bibr" rid="cit0020">20</xref></sup>. Therefore, the present meta-analysis was performed to determine the association between <italic>CYP2A6</italic> whole-gene deletion (<italic>CYP2A6*4</italic>) polymorphism and lung cancer risk.</p>
</sec>
<sec id="sec2" sec-type="methods">
<title>METHODS</title>
<sec id="sec2.1">
<title>Literature search</title>
<p>This meta-analysis was performed based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement<sup><xref ref-type="bibr" rid="cit0021">21</xref></sup>. A literature search was performed on five databases, namely PubMed, SAGE, ScienceDirect, the Cochrane Library, and Ovid. The search strategy utilized the PICO (Population, Intervention, Comparison, Outcome) framework to improve searching for clinical questions<sup><xref ref-type="bibr" rid="cit0022">22</xref></sup>. The search terms used were: [‘cytochrome P450 2A6’ OR ‘<italic>CYP2A6</italic>’] AND [‘lung cancer’ OR ‘pulmonary cancer’ OR ‘respiratory cancer’]. The search was not restricted to any duration or timeline.</p>
</sec>
<sec id="sec2.2">
<title>Study selection</title>
<p>Two pairs of reviewers conducted the study selection in two phases after duplicate studies had been excluded. In the first phase, two reviewers (MSAM and MHA) independently screened the titles and abstracts of potential articles to be included in the study. During this phase, irrelevant studies were excluded, and a third reviewer (FHJ) resolved any disagreements. In the second phase, full-text articles were retrieved for detailed evaluation. Studies were included if they were published prior to October 2018 and met the following criteria: 1) observational study design, 2) presence of <italic>CYP2A6</italic> whole-gene deletion (<italic>CYP2A6*4</italic>) polymorphism, and 3) presence of lung cancer. We excluded studies that were not published in English, reviews, case reports or animal studies, or if the full text was not available.</p>
</sec>
<sec id="sec2.3">
<title>Data extraction</title>
<p>Articles that met the inclusion and exclusion criteria were retained for a full review. The characteristics of each study were examined and included study design, study location, type of population, sample size, sex, smoking status, matching criteria, genotyping method and genotype, and risk estimate value.</p>
</sec>
<sec id="sec2.4">
<title>Assessment of methodological quality</title>
<p>Two authors assessed the quality of the selected articles independently, using the Newcastle-Ottawa Quality Assessment Scale (NOS)<sup><xref ref-type="bibr" rid="cit0023">23</xref></sup> to examine for the concordance and average NOS score for each study. The NOS is widely used for quality assessment of observational studies<sup><xref ref-type="bibr" rid="cit0024">24</xref>,<xref ref-type="bibr" rid="cit0025">25</xref></sup>. It evaluates three components to quantify study quality, i.e. selection of study subjects, comparability of study groups and exposure or outcome ascertainment, which consists of eight items with a maximum score of 9 for each study. The scores of each item indicate the methodological quality of the study. A study is categorized as being of high, moderate or low quality, based on a total score of 7–9, 4–6 and 0–3, respectively<sup><xref ref-type="bibr" rid="cit0026">26</xref></sup>.</p>
</sec>
<sec id="sec2.5">
<title>Meta-analysis</title>
<p>The random-effects model<sup><xref ref-type="bibr" rid="cit0027">27</xref></sup> was used to estimate the pooled effect size from the included studies. Odds ratio (OR) with 95% confidence interval (CI) and a statistical measure of heterogeneity (χ<sup><xref ref-type="bibr" rid="cit0002">2</xref></sup> and I<sup><xref ref-type="bibr" rid="cit0002">2</xref></sup>) were calculated using Review Manager 5.3<sup><xref ref-type="bibr" rid="cit0028">28</xref></sup>. All selected studies were included in the meta-analysis. Subgroup and sensitivity analyses were performed if p&lt;0.10 and I<sup><xref ref-type="bibr" rid="cit0002">2</xref></sup> ≥50%.</p>
</sec>
</sec>
<sec id="sec3" sec-type="results">
<title>RESULTS</title>
<p>The search strategy returned a total of 172 articles. Initial screening excluded 35 articles due to duplication. Further screening of titles and abstracts excluded 41 irrelevant studies and nine review articles. The eligibility of the remaining 87 articles was assessed: 40 were excluded for studying different outcomes such as smoking behaviour, 28 were excluded for studying different exposures such as other CYP450 genotypes, eight were excluded as we were unable to extract raw data related to the whole deletion of allele *4/*4, while two articles were excluded because we did not find data related to the whole deletion of allele *4/*4 in the studies. The remaining nine articles<sup><xref ref-type="bibr" rid="cit0012">12</xref>,<xref ref-type="bibr" rid="cit0020">20</xref>,<xref ref-type="bibr" rid="cit0029">29</xref>-<xref ref-type="bibr" rid="cit0035">35</xref></sup> were included in the meta-analysis. <xref ref-type="fig" rid="f0001">Figure 1</xref> depicts the flow diagram describing article retrieval based on the PRISMA flow diagram<sup><xref ref-type="bibr" rid="cit0021">21</xref></sup>. The studies were carried out in Japan, China, Bangladesh, and Italy. Eight studies used Asian samples and only one study<sup><xref ref-type="bibr" rid="cit0034">34</xref></sup> used Caucasian samples. <xref ref-type="table" rid="t0001">Tables 1</xref> and <xref ref-type="table" rid="t0002">2</xref> present the characteristics of the included studies.</p>
<table-wrap id="t0001" position="float">
<label>Table 1</label>
<caption>
<p>Characteristics of studies included in the meta-analysis</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">
<italic>Study</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>Year Country &amp; Population</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>Study design (cases/controls)</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>Gender, Smoking status</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>Matching criteria</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>Genotyping methods</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>Histological type (%)</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>CYP2A6 genotype</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>Crude OR (95% CI)</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Hosono et al.<sup><xref ref-type="bibr" rid="cit0012">12</xref></sup></td>
<td align="left" colspan="1" rowspan="1">2015 Japan<break></break>Asian</td>
<td align="left" colspan="1" rowspan="1">Case-control<break></break>110/132</td>
<td align="left" colspan="1" rowspan="1">Both<break></break>All smoker</td>
<td align="left" colspan="1" rowspan="1">Age, sex</td>
<td align="left" colspan="1" rowspan="1">PCR-Goodz and Tyndale</td>
<td align="left" colspan="1" rowspan="1">SQCC (100)</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1/1<break></break>Group 2: 1/7, 1/9,<break></break>1/10, 1/13, 1/15, 8/9<break></break>Group 3: 1/4, 1/41,<break></break>1/567C&gt;T, 7/9, 7/11,<break></break>7/13, 9/9, 9/11<break></break>Group 4: 4/7, 4/9,<break></break>4/13, 4/18, 7/567C&gt;T<break></break>Group 5: 4/4, 4/5</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1 (Ref.)<break></break>Group 2: 1.00 (0.49–2.07)<break></break>Group 3: 0.71 (0.35–1.45)<break></break>Group 4: 0.13 (0.04–0.45)<break></break>Group 5: 0.15 (0.03–0.82)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Islam et al.<sup><xref ref-type="bibr" rid="cit0029">29</xref></sup></td>
<td align="left" colspan="1" rowspan="1">2013<break></break>Bangladesh<break></break>Asian</td>
<td align="left" colspan="1" rowspan="1">Case-control<break></break>106/116</td>
<td align="left" colspan="1" rowspan="1">Both<break></break>Mixed</td>
<td align="left" colspan="1" rowspan="1">Age, sex, smoking status</td>
<td align="left" colspan="1" rowspan="1">PCR-RFLP</td>
<td align="left" colspan="1" rowspan="1">SQCC (43.39)<break></break>AC (34.91<break></break>SCC (18.87)<break></break>ASQC (0.94)</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1A/1A,<break></break>1A/1B1, 1B1/1B1.<break></break>Group 2: 1A/4,<break></break>1B1/4. 4/4</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1 (Ref.)<break></break>Group 2: 0.40 (0.17–0.91)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tamaki et al.<sup><xref ref-type="bibr" rid="cit0030">30</xref></sup></td>
<td align="left" colspan="1" rowspan="1">2011 Japan<break></break>Asian</td>
<td align="left" colspan="1" rowspan="1">Case-control<break></break>192/203</td>
<td align="left" colspan="1" rowspan="1">Both<break></break>Mixed</td>
<td align="left" colspan="1" rowspan="1">Age, sex</td>
<td align="left" colspan="1" rowspan="1">PCR- Oscarson</td>
<td align="left" colspan="1" rowspan="1">AC (41.7)<break></break>SQCC (24.5)<break></break>SCC (21.4)<break></break>ASQC (2.1)<break></break>LCC (0.5)<break></break>Unknown (3.6)</td>
<td align="left" colspan="1" rowspan="1">Group 1: non-4/<break></break>non-4<break></break>Group 2: non-4/4<break></break>Group 3: 4/4</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1 (Ref.)<break></break>Group 2: 0.92 (0.60–1.42)<break></break>Group 3: 0.36 (0.14–0.88)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Rotunno et al.<sup><xref ref-type="bibr" rid="cit0034">34</xref></sup></td>
<td align="left" colspan="1" rowspan="1">2009 Italy<break></break>Caucasian</td>
<td align="left" colspan="1" rowspan="1">Case-control<break></break>1859/2019</td>
<td align="left" colspan="1" rowspan="1">Both<break></break>Mixed</td>
<td align="left" colspan="1" rowspan="1">Age, sex, area of residence</td>
<td align="left" colspan="1" rowspan="1">SNP Assays</td>
<td align="left" colspan="1" rowspan="1">AC (41)<break></break>SQCC (25.6)<break></break>SCC (10.2)<break></break>Other (21.5)<break></break>Unknown (1.8)</td>
<td align="left" colspan="1" rowspan="1">Group 1: T/T<break></break>Group 2: T/A<break></break>Group 3: A/A</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1 (Ref.)<break></break>Group 2: 0.74 (0.55–1.00)<break></break>Group 3: 0.26 (0.04–1.94)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fujieda et al.<sup><xref ref-type="bibr" rid="cit0031">31</xref></sup></td>
<td align="left" colspan="1" rowspan="1">2004 Japan<break></break>Asian</td>
<td align="left" colspan="1" rowspan="1">Case-control<break></break>1094/611</td>
<td align="left" colspan="1" rowspan="1">Both<break></break>All smokers</td>
<td align="left" colspan="1" rowspan="1">No matching</td>
<td align="left" colspan="1" rowspan="1">PCR-RFLP</td>
<td align="left" colspan="1" rowspan="1">SQCC (26.9)<break></break>SCC (12.2)<break></break>AC (50.9)<break></break>Unknown<break></break>(10.0)</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1/1<break></break>Group 2: 1/4, 1/7,<break></break>1/9, 1/10, 1/11<break></break>Group 3: 4/7, 4/9,<break></break>4/10, 4/11, 7/7, 7/9,<break></break>7/10, 9/9, 9/10, 9/11,<break></break>10/10<break></break>Group 4: 4/4</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1 (Ref.)<break></break>Group 2: 0.59 (0.44–0.79)<xref ref-type="table-fn" rid="tf1-1"><sup>a</sup></xref><break></break>Group 3: 0.52 (0.37–0.72)<sup>a</sup><break></break>Group 4: 0.30 (0.16–0.57)<xref ref-type="table-fn" rid="tf1-1"><sup>a</sup></xref></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ariyoshi et al.<sup><xref ref-type="bibr" rid="cit0032">32</xref></sup></td>
<td align="left" colspan="1" rowspan="1">2002 Japan<break></break>Asian</td>
<td align="left" colspan="1" rowspan="1">Case-control<break></break>370/380</td>
<td align="left" colspan="1" rowspan="1">Both<break></break>All smokers</td>
<td align="left" colspan="1" rowspan="1">No matching</td>
<td align="left" colspan="1" rowspan="1">PCR-Bell</td>
<td align="left" colspan="1" rowspan="1">SCC (11.9)<break></break>SQCC (28.4)<break></break>AC (52.1)<break></break>Others (7.6)</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1A/1A<break></break>Group 2: 1A/1B<break></break>Group 3: 1B/1B<break></break>Group 4: 1A/4<break></break>Group 5: 1B/4<break></break>Group 6: 4/4</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1 (Ref.)<break></break>Group 2: 0.70 (0.46–1.07)<break></break>Group 3: 0.60 (0.37–0.99)<break></break>Group 4: 0.57 (0.33–0.97)<break></break>Group 5: 0.56 (0.34–0.92)<break></break>Group 6: 0.18 (0.06–0.50)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tan et al.<sup><xref ref-type="bibr" rid="cit0020">20</xref></sup></td>
<td align="left" colspan="1" rowspan="1">2001 China<break></break>Asian</td>
<td align="left" colspan="1" rowspan="1">Case-control<break></break>151/326</td>
<td align="left" colspan="1" rowspan="1">Both<break></break>Mixed</td>
<td align="left" colspan="1" rowspan="1">Age, sex</td>
<td align="left" colspan="1" rowspan="1">PCR-Oscarson</td>
<td align="left" colspan="1" rowspan="1">SCC (58.3)<break></break>AC (31.1)<break></break>Other (10.6)</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1/1<break></break>Group 2: 1/4, 4/4</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1 (Ref.)<break></break>Group 2: 2.0 (1.2–3.2)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Miyamoto et al.<sup><xref ref-type="bibr" rid="cit0033">33</xref></sup></td>
<td align="left" colspan="1" rowspan="1">1999 Japan<break></break>Asian</td>
<td align="left" colspan="1" rowspan="1">Case-control<break></break>246/201</td>
<td align="left" colspan="1" rowspan="1">Both<break></break>NA</td>
<td align="left" colspan="1" rowspan="1">No matching</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">Group 1: Wild/Wild<break></break>Group 2: Wild/Conv.<break></break>Group 3: Conv./Conv.<break></break>Group 4: Wild/Del.<break></break>Group 5: Conv./Del.<break></break>Group 6: Del./Del.</td>
<td align="left" colspan="1" rowspan="1">Group 1: 1 (Ref.)<break></break>Group 2: 0.59 (0.34–1.02)<break></break>Group 3: 0.57 (0.30–1.08)<break></break>Group 4: 0.29 (0.14–0.59)<break></break>Group 5: 0.46 (0.23–0.92)<break></break>Group 6: 0.25 (0.08–0.83)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Kamataki et al.<sup><xref ref-type="bibr" rid="cit0035">35</xref></sup></td>
<td align="left" colspan="1" rowspan="1">1999 Japan<break></break>Asian</td>
<td align="left" colspan="1" rowspan="1">Case-control<break></break>257/154</td>
<td align="left" colspan="1" rowspan="1">Both<break></break>NA</td>
<td align="left" colspan="1" rowspan="1">No matching</td>
<td align="left" colspan="1" rowspan="1">PCR-RFLP</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">NA</td>
<td align="left" colspan="1" rowspan="1">NA</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tf1-1">
<label>a</label>
<p>Adjusted for age and smoking habit.</p>
</fn>
<fn>
<p>PCR-RFLP: Polymerase Chain Reaction - Restriction Fragment Length Polymorphism. Del: Deletion-type, Conv: Conversion-type. SQCC: Squamous Cell Carcinoma. AC: Adenocarcinoma. SCC: Small Cell Carcinoma. ASQC: Adenosquamous Cell Carcinoma. LCC: Large Cell Carcinoma.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="t0002" position="float">
<label>Table 2</label>
<caption>
<p>Genotype frequencies of CYP2A6*4 in studies included in the meta-analysis</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="3" valign="top">
<italic>Author</italic>
</th>
<th align="center" colspan="1" rowspan="3" valign="top">
<italic>Year</italic>
</th>
<th align="center" colspan="3" rowspan="1">
<italic>Case Genotype</italic>
</th>
<th align="center" colspan="3" rowspan="1">
<italic>Control Genotype</italic>
</th>
</tr>
<tr>
<th align="center" colspan="6" rowspan="1">
<hr/>
</th>
</tr>
<tr>
<th align="center" colspan="1" rowspan="1">
<italic>*4/*4</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>*4/non-*4</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>non-*4/non-*4</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>*4/*4</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>*4/non-*4</italic>
</th>
<th align="center" colspan="1" rowspan="1">
<italic>non-*4/non-*4</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Hosono et al.<sup><xref ref-type="bibr" rid="cit0012">12</xref></sup></td>
<td align="center" colspan="1" rowspan="1">2015</td>
<td align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">32</td>
<td align="center" colspan="1" rowspan="1">76</td>
<td align="center" colspan="1" rowspan="1">8</td>
<td align="center" colspan="1" rowspan="1">48</td>
<td align="center" colspan="1" rowspan="1">76</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Islam et al.<sup><xref ref-type="bibr" rid="cit0029">29</xref></sup></td>
<td align="center" colspan="1" rowspan="1">2013</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">8</td>
<td align="center" colspan="1" rowspan="1">97</td>
<td align="center" colspan="1" rowspan="1">4</td>
<td align="center" colspan="1" rowspan="1">18</td>
<td align="center" colspan="1" rowspan="1">94</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tamaki et al.<sup><xref ref-type="bibr" rid="cit0030">30</xref></sup></td>
<td align="center" colspan="1" rowspan="1">2011</td>
<td align="center" colspan="1" rowspan="1">7</td>
<td align="center" colspan="1" rowspan="1">63</td>
<td align="center" colspan="1" rowspan="1">122</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">66</td>
<td align="center" colspan="1" rowspan="1">118</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Rotunno et al.<sup><xref ref-type="bibr" rid="cit0034">34</xref></sup></td>
<td align="center" colspan="1" rowspan="1">2009</td>
<td align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">101</td>
<td align="center" colspan="1" rowspan="1">1756</td>
<td align="center" colspan="1" rowspan="1">4</td>
<td align="center" colspan="1" rowspan="1">160</td>
<td align="center" colspan="1" rowspan="1">1855</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Fujieda et al.<sup><xref ref-type="bibr" rid="cit0031">31</xref></sup></td>
<td align="center" colspan="1" rowspan="1">2004</td>
<td align="center" colspan="1" rowspan="1">25</td>
<td align="center" colspan="1" rowspan="1">301</td>
<td align="center" colspan="1" rowspan="1">768</td>
<td align="center" colspan="1" rowspan="1">28</td>
<td align="center" colspan="1" rowspan="1">186</td>
<td align="center" colspan="1" rowspan="1">397</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ariyoshi et al.<sup><xref ref-type="bibr" rid="cit0032">32</xref></sup></td>
<td align="center" colspan="1" rowspan="1">2002</td>
<td align="center" colspan="1" rowspan="1">5</td>
<td align="center" colspan="1" rowspan="1">98</td>
<td align="center" colspan="1" rowspan="1">267</td>
<td align="center" colspan="1" rowspan="1">19</td>
<td align="center" colspan="1" rowspan="1">117</td>
<td align="center" colspan="1" rowspan="1">244</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Tan et al.<sup><xref ref-type="bibr" rid="cit0020">20</xref></sup></td>
<td align="center" colspan="1" rowspan="1">2001</td>
<td align="center" colspan="1" rowspan="1">1</td>
<td align="center" colspan="1" rowspan="1">38</td>
<td align="center" colspan="1" rowspan="1">112</td>
<td align="center" colspan="1" rowspan="1">5</td>
<td align="center" colspan="1" rowspan="1">46</td>
<td align="center" colspan="1" rowspan="1">275</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Miyamoto et al.<sup><xref ref-type="bibr" rid="cit0033">33</xref></sup></td>
<td align="center" colspan="1" rowspan="1">1999</td>
<td align="center" colspan="1" rowspan="1">5</td>
<td align="center" colspan="1" rowspan="1">48</td>
<td align="center" colspan="1" rowspan="1">193</td>
<td align="center" colspan="1" rowspan="1">9</td>
<td align="center" colspan="1" rowspan="1">60</td>
<td align="center" colspan="1" rowspan="1">132</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Kamataki et al.<sup><xref ref-type="bibr" rid="cit0035">35</xref></sup></td>
<td align="center" colspan="1" rowspan="1">1999</td>
<td align="center" colspan="1" rowspan="1">2</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">255</td>
<td align="center" colspan="1" rowspan="1">6</td>
<td align="center" colspan="1" rowspan="1">-</td>
<td align="center" colspan="1" rowspan="1">148</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="f0001" position="float">
<label>Figure 1</label>
<caption>
<p>Flow chart of studies selection</p>
</caption>
<graphic xlink:href="TID-18-50-g001"></graphic>
</fig>
<p>Two reviewers were independently assigned to score the NOS for each study individually. The correlation coefficient scores between the two authors were strong, with r = 0.91 (<xref ref-type="fig" rid="f0002">Figure 2</xref>). Overall, the studies had moderate methodological quality as scored on NOS (mean score: 6.0; range: 2.0–7.5). Four studies were of high quality (NOS score: 7.0– 9.0)<sup><xref ref-type="bibr" rid="cit0020">20</xref>,<xref ref-type="bibr" rid="cit0029">29</xref>,<xref ref-type="bibr" rid="cit0032">32</xref>,<xref ref-type="bibr" rid="cit0034">34</xref></sup>, four were of moderate quality (NOS score: 4.0–6.9)<sup><xref ref-type="bibr" rid="cit0021">21</xref>,<xref ref-type="bibr" rid="cit0031">31</xref>,<xref ref-type="bibr" rid="cit0032">32</xref>,<xref ref-type="bibr" rid="cit0034">34</xref></sup>, and only one study was of low quality (NOS score: &lt;4.0)<sup><xref ref-type="bibr" rid="cit0035">35</xref></sup>. The shape and symmetry of the funnel plot of log OR from the nine studies indicated that there was no publication bias (<xref ref-type="fig" rid="f0003">Figure 3</xref>). All studies had a high precision value.</p>
<fig id="f0002" position="float">
<label>Figure 2</label>
<caption>
<p>The research quality assessment of each study was assessed using NOS with two independent reviewers.</p>
</caption>
<graphic xlink:href="TID-18-50-g002"></graphic>
</fig>
<fig id="f0003" position="float">
<label>Figure 3</label>
<caption>
<p>Funnel plot of the nine studies included in the meta-analysis</p>
</caption>
<graphic xlink:href="TID-18-50-g003"></graphic>
</fig>
<p><xref ref-type="fig" rid="f0004">Figure 4</xref> shows the result of the meta-analysis using the random-effects model 28, which combined the nine studies to explore the association between the <italic>CYP2A6*4</italic> polymorphism and the risk of lung cancer. The forest plot illustrates the spread of the studies’ risk estimates and their CIs in relation to the pooled OR of meta-analysis. The pooled OR estimates showed that the <italic>CYP2A6*4</italic> whole-gene deletion polymorphism significantly reduced the risk of lung cancer (pooled OR=0.39; 95% CI: 0.27–0.56). No heterogeneity was found across the studies (pheterogeneity = 0.96, I2=0%). Subgroup analysis according to smoking status (<xref ref-type="fig" rid="f0005">Figure 5</xref>) showed that the pooled OR estimate of the <italic>CYP2A6*4</italic> whole-gene deletion polymorphism remained significantly protective against lung cancer among ‘All Smoker Status’ (pooled OR=0.41; 95% CI: 0.26–0.64), ‘Mixed Smoking Status’ (pooled OR=0.39; 95% CI: 0.19–0.78) and ‘Unknown Smoking Status’.</p>
<fig id="f0004" position="float">
<label>Figure 4</label>
<caption>
<p>Forest plot analysis</p>
</caption>
<graphic xlink:href="TID-18-50-g004"></graphic>
</fig>
<fig id="f0005" position="float">
<label>Figure 5</label>
<caption>
<p>Subgroup analysis according to smoking status</p>
</caption>
<graphic xlink:href="TID-18-50-g005"></graphic>
</fig>
</sec>
<sec id="sec4" sec-type="discussion">
<title>DISCUSSION</title>
<p>A comprehensive search of different databases was used to yield the most relevant results and incorporated the available epidemiologic evidence to explore the relationship between the <italic>CYP2A6*4</italic> whole-gene deletion polymorphism and the risk of lung cancer. Nine case-control studies fulfilled the criteria addressing this issue. The analysis, involving 4385 lung cancer cases and 4142 controls, suggested that <italic>CYP2A6</italic> polymorphism significantly reduces the risk of lung cancer (pooled OR=0.39; 95% CI: 0.27–0.56), with homogeneity observed across studies (χ<sup>2</sup>=2.49, p=0.96, I<sup>2</sup>=0%). Thus, subgroup and sensitivity analyses were not explored.</p>
<p>There are two possible explanations for the finding of relative risk reduction as revealed by the analysis. First, <italic>CYP2A6</italic> is mainly found in the liver and other tissues such as the nasal epithelium, trachea, lung, and oesophagus<sup><xref ref-type="bibr" rid="cit0036">36</xref>,<xref ref-type="bibr" rid="cit0037">37</xref></sup>. <italic>CYP2A6</italic> metabolizes a few but specific xenobiotics that include nicotine and some tobacco specific nitrosamines that enter the human body. Metabolic activation by <italic>CYP2A6</italic> enzymes generally produces a short-lived electrophile agent that reacts with DNA, causing DNA damage and inducing a tumour<sup><xref ref-type="bibr" rid="cit0016">16</xref></sup>. In tobacco smoke, <italic>CYP2A6</italic> is the main enzyme activating the tobacco-specific <italic>N</italic>-nitrosamines NNK and NNN, which are pro-carcinogens<sup><xref ref-type="bibr" rid="cit0005">5</xref>,<xref ref-type="bibr" rid="cit0006">6</xref></sup>. Thus, in individuals with the inactive <italic>CYP2A6</italic> genotype, the <italic>CYP2A6</italic> enzyme might not affect metabolic activation of N-nitrosamines and subsequently reduce the risk of lung cancer. Second, <italic>CYP2A6</italic> is a major enzyme responsible for nicotine metabolism<sup><xref ref-type="bibr" rid="cit0038">38</xref></sup>, where inactive <italic>CYP2A6</italic> causes lower nicotine dependence and thus affects smoking behaviour<sup><xref ref-type="bibr" rid="cit0039">39</xref>-<xref ref-type="bibr" rid="cit0041">41</xref></sup>.</p>
<p>Of the included studies, only three studies<sup><xref ref-type="bibr" rid="cit0012">12</xref>,<xref ref-type="bibr" rid="cit0031">31</xref>,<xref ref-type="bibr" rid="cit0032">32</xref></sup> recruited only smokers as participants; the remaining studies had mixed populations of smokers and never-smokers. The mixed-smoker status studies yielded non-significant findings or smaller risk estimates, which may be explained by the fact that the probability of lung cancer occurrence may be similar among never-smokers with different <italic>CYP2A6</italic> genotypes, where the resulting phenotype is not expressed in people who do not smoke. Thus, when the original studies included both smokers and non-smokers, the association between the <italic>CYP2A6</italic> polymorphism genotype and risk of lung cancer may have been attenuated. This may explain why some of the studies did not find any significant association<sup><xref ref-type="bibr" rid="cit0019">19</xref>,<xref ref-type="bibr" rid="cit0020">20</xref>,<xref ref-type="bibr" rid="cit0029">29</xref>,<xref ref-type="bibr" rid="cit0042">42</xref></sup>.</p>
<p>Besides that, cigarette smoking is strongly associated with squamous cell carcinoma compared to adenocarcinoma<sup><xref ref-type="bibr" rid="cit0043">43</xref>-<xref ref-type="bibr" rid="cit0045">45</xref></sup>. However, in the present meta-analysis, all but one study included different lung cancer histology types; Hosono et al.<sup><xref ref-type="bibr" rid="cit0012">12</xref></sup> only recruited squamous cell carcinoma cases. The study by Islam et al.<sup><xref ref-type="bibr" rid="cit0029">29</xref></sup> had the highest proportion of squamous cell carcinoma cases (43.39%), while the other studies had 24.5–28.4% squamous cell carcinoma cases<sup><xref ref-type="bibr" rid="cit0030">30</xref>-<xref ref-type="bibr" rid="cit0032">32</xref>,<xref ref-type="bibr" rid="cit0034">34</xref></sup>. These differences in the proportion of histological types might explain the discrepancy of the findings among the studies on <italic>CYP2A6</italic> polymorphism and lung cancer risk.</p>
<sec id="sec4.1">
<title>Limitations</title>
<p>The present meta-analysis findings should be interpreted with caution. Six studies did not stratify the smoking status to assess the association between <italic>CYP2A6</italic> polymorphism and lung cancer. Therefore, the true relationship between <italic>CYP2A6</italic> polymorphism and risk of lung cancer in current-smokers and never-smokers could not be tested in these six studies. In addition, lung cancer might arise due to occupational carcinogen exposure, such as organic dust and silica dust<sup><xref ref-type="bibr" rid="cit0046">46</xref>,<xref ref-type="bibr" rid="cit0047">47</xref></sup>, which may confound the association between <italic>CYP2A6</italic> polymorphism and lung cancer risk. However, none of the included studies adjusted for occupational carcinogen hazard exposure originally. The relationship may be also affected by differences in the demographic characteristics and socioeconomic class of the respondents<sup><xref ref-type="bibr" rid="cit0048">48</xref></sup>, which some of the studies did not mention.</p>
</sec>
</sec>
<sec id="sec5" sec-type="conclusions">
<title>CONCLUSIONS</title>
<p>The evidence from the case-control studies included in the present meta-analysis shows that people with <italic>CYP2A6*4</italic> whole-gene deletion have a decreased risk of lung cancer. Further research is needed to identify any potential confounding factors that may impact this association.</p>
</sec>
</body>
<back>
<sec sec-type="COI-statement">
<title>CONFLICTS OF INTEREST</title>
<p>The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none was reported.</p>
</sec>
<sec>
<title>FUNDING</title>
<p>There was no source of funding for this research.</p>
</sec>
<sec>
<title>AUTHORS’ CONTRIBUTIONS</title>
<p>AMN initiated the idea and also designed the current study. FHJ and MSAM, simultaneously performed independent searches and also conducted the subjective as well as the objective quality assessment of the retrieved articles. MHA screened the titles and abstracts of the retrieved articles to identify the relevance of the reports to the objective of this review using the eligibility criteria. All four authors contributed in the final synthesis and writing of the manuscript. FHJ and MSAM performed the meta-analysis for this study.</p>
</sec>
<sec>
<title>PROVENANCE AND PEER REVIEW</title>
<p>Not commissioned; externally peer reviewed.</p>
</sec>
<ref-list>
<title>REFERENCES</title>
<ref id="cit0001">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bray</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ferlay</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Soerjomataram</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Torre</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Jemal</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>
<source/>CA Cancer J Clin
          <year>2018</year>
<volume>68</volume>
<fpage>394</fpage>
<lpage>424</lpage>
<pub-id pub-id-type="doi">10.3322/caac.21492</pub-id>
<pub-id pub-id-type="pmid">30207593</pub-id>
</element-citation>
</ref>
<ref id="cit0002">
<label>2</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>World Health Organization, International Agency for Research on Cancer</collab>
</person-group>
<source/>Tobacco smoke and involuntary smoking. Volume 83 of IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
          <year>2004</year>
<publisher-loc>Lyon, France</publisher-loc>
<publisher-name>International Agency for Research on Cancer</publisher-name>
<comment><ext-link ext-link-type="uri" xlink:href="https://monographs.iarc.fr/wp-content/uploads/2018/06/mono83.pdf">https://monographs.iarc.fr/wp-content/uploads/2018/06/mono83.pdf</ext-link>. Accessed December 30, 2019</comment>
</element-citation>
</ref>
<ref id="cit0003">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Parent</surname>
<given-names>MÉ</given-names>
</name>
<name>
<surname>Hanley</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Exposure to environmental tobacco smoke and the risk of lung cancer: a meta-analysis</article-title>
<source/>Lung Cancer
          <year>2000</year>
<volume>27</volume>
<fpage>3</fpage>
<lpage>18</lpage>
<pub-id pub-id-type="doi">10.1016/s0169-5002(99)00093-8</pub-id>
<pub-id pub-id-type="pmid">10672779</pub-id>
</element-citation>
</ref>
<ref id="cit0004">
<label>4</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gumming</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Woodward</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Black</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Passive smoking and lung cancer: a cumulative meta-analysis</article-title>
<source/>Aust N Z J Public Health
          <year>2001</year>
<volume>25</volume>
<fpage>203</fpage>
<lpage>211</lpage>
<pub-id pub-id-type="doi">10.1111/j.1467-842x.2001.tb00564.x</pub-id>
<pub-id pub-id-type="pmid">11494987</pub-id>
</element-citation>
</ref>
<ref id="cit0005">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crespi</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Penman</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Gelboin</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>FJ</given-names>
</name>
</person-group>
<article-title>A tobacco smoke-derived nitrosamine, 4-(methytnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytocbrome P450s including the polymorphic human cytochrome P4502D6</article-title>
<source/>Carcinogenesis
          <year>1991</year>
<volume>12</volume>
<fpage>1197</fpage>
<lpage>1201.</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/12.7.1197</pub-id>
<pub-id pub-id-type="pmid">2070484</pub-id>
</element-citation>
</ref>
<ref id="cit0006">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hecht</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>CHB</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>A study of tobacco carcinogenesis. 17. Tobacco-specific nitrosamines: occurrence, formation, carcinogenicity, and metabolism</article-title>
<source/>Acc Chem Res
          <year>1979</year>
<volume>12</volume>
<fpage>92</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="doi">10.1021/ar50135a003</pub-id>
</element-citation>
</ref>
<ref id="cit0007">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spitz</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Amos</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Genetic susceptibility to lung cancer: the role of DNA damage and repair</article-title>
<source/>Cancer Epidemiol Biomarkers Prev
          <year>2003</year>
<volume>12</volume>
<fpage>689</fpage>
<lpage>698</lpage>
<pub-id pub-id-type="pmid">12917198</pub-id>
</element-citation>
</ref>
<ref id="cit0008">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matakidou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eisen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Houlston</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Systematic review of the relationship between family history and lung cancer risk</article-title>
<source/>Br J Cancer
          <year>2005</year>
<volume>93</volume>
<fpage>825</fpage>
<pub-id pub-id-type="doi">10.1038/sj.bjc.6602769</pub-id>
<pub-id pub-id-type="pmid">16160696</pub-id>
</element-citation>
</ref>
<ref id="cit0009">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Aunan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Seip</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Air pollution and lung cancer risks in China—a meta-analysis</article-title>
<source/>Sci Total Environ
          <year>2006</year>
<volume>366</volume>
<fpage>500</fpage>
<lpage>513</lpage>
<pub-id pub-id-type="doi">10.1016/j.scitotenv.2005.10.010</pub-id>
<pub-id pub-id-type="pmid">16406110</pub-id>
</element-citation>
</ref>
<ref id="cit0010">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hamra</surname>
<given-names>GB</given-names>
</name>
<name>
<surname>Guha</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Outdoor particulate matter exposure and lung cancer: a systematic review and meta-analysis</article-title>
<source/>Environ Health Perspect
          <year>2014</year>
<volume>122</volume>
<issue>9</issue>
<pub-id pub-id-type="doi">10.1289/ehp/1408092</pub-id>
</element-citation>
</ref>
<ref id="cit0011">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Celik</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gallicchio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Boyd</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Arsenic in drinking water and lung cancer: a systematic review</article-title>
<source/>Environ Res
          <year>2008</year>
<volume>108</volume>
<fpage>48</fpage>
<lpage>55</lpage>
<pub-id pub-id-type="doi">10.1016/j.envres.2008.04.001</pub-id>
<pub-id pub-id-type="pmid">18511031</pub-id>
</element-citation>
</ref>
<ref id="cit0012">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hosono</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kumondai</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>CYP2A6</italic> genetic polymorphism is associated with decreased susceptibility to squamous cell lung cancer in Japanese smokers</article-title>
<source/>Drug Metab Pharmacokinet
          <year>2015</year>
<volume>30</volume>
<fpage>263</fpage>
<lpage>268</lpage>
<pub-id pub-id-type="doi">10.1016/j.dmpk.2015.04.002</pub-id>
<pub-id pub-id-type="pmid">26091970</pub-id>
</element-citation>
</ref>
<ref id="cit0013">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goode</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Ulrich</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Potter</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>Polymorphisms in DNA repair genes and associations with cancer risk</article-title>
<source/>Cancer Epidemiol Biomarkers Prev
          <year>2002</year>
<volume>11</volume>
<fpage>1513</fpage>
<lpage>1530</lpage>
<pub-id pub-id-type="pmid">12496039</pub-id>
</element-citation>
</ref>
<ref id="cit0014">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yamazaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Inui</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yun</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Guengerich</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes</article-title>
<source/>Carcinogenesis
          <year>1992</year>
<volume>13</volume>
<fpage>1789</fpage>
<lpage>1794</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/13.10.1789</pub-id>
<pub-id pub-id-type="pmid">1423839</pub-id>
</element-citation>
</ref>
<ref id="cit0015">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Guengerich</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Shimada</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Activation of procarcinogens by human cytochrome P450 enzymes</article-title>
<source/>Mutat Res
          <year>1998</year>
<volume>400</volume>
<fpage>201</fpage>
<lpage>213</lpage>
<pub-id pub-id-type="doi">10.1016/s0027-5107(98)00037-2</pub-id>
<pub-id pub-id-type="pmid">9685642</pub-id>
</element-citation>
</ref>
<ref id="cit0016">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakajima</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamamoto</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nunoya</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Role of human cytochrome P4502A6 in C-oxidation of nicotine</article-title>
<source/>Drug Metab Dispos
          <year>1996</year>
<volume>24</volume>
<fpage>1212</fpage>
<lpage>1217</lpage>
<pub-id pub-id-type="pmid">8937855</pub-id>
</element-citation>
</ref>
<ref id="cit0017">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ismail</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Essawi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Genetic polymorphism studies in humans</article-title>
<source/>Middle East Journal of Medical Genetics
          <year>2012</year>
<volume>1</volume>
<fpage>57</fpage>
<lpage>63</lpage>
<pub-id pub-id-type="doi">10.1097/01.mxe.0000415225.85003.47</pub-id>
</element-citation>
</ref>
<ref id="cit0018">
<label>18</label>
<element-citation publication-type="webpage">
<person-group person-group-type="author">
<name>
<surname>Phillips</surname>
<given-names>T</given-names>
</name>
</person-group>
<source/>Genetic Polymorphism—Different Does Not Mean Mutated: Multiple Forms of a Single Gene
          <comment><ext-link ext-link-type="uri" xlink:href="https://www.thebalance.com/genetic-polymorphism-what-is-it-375594">https://www.thebalance.com/genetic-polymorphism-what-is-it-375594</ext-link>. Accessed December 18, 2018</comment>
</element-citation>
</ref>
<ref id="cit0019">
<label>19</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Loriot</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rebuissou</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Oscarson</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic polymorphisms of cytochrome P450 2A6 in a case–control study on lung cancer in a French population</article-title>
<source/>Pharmacogenetics
          <year>2001</year>
<volume>11</volume>
<fpage>39</fpage>
<lpage>44</lpage>
<pub-id pub-id-type="doi">10.1097/00008571-200102000-00005</pub-id>
<pub-id pub-id-type="pmid">11207029</pub-id>
</element-citation>
</ref>
<ref id="cit0020">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>Xing</surname>
<given-names>DY</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>CY</given-names>
</name>
<name>
<surname>Kadlubar</surname>
<given-names>FF</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>DX</given-names>
</name>
</person-group>
<article-title>Frequency of <italic>CYP2A6</italic> gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population</article-title>
<source/>Int J Cancer
          <year>2001</year>
<volume>95</volume>
<fpage>96</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="doi">10.1002/1097-0215(20010320)95:2&lt;96::aid-ijc1017&gt;3.0.co;2-2</pub-id>
<pub-id pub-id-type="pmid">11241319</pub-id>
</element-citation>
</ref>
<ref id="cit0021">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moher</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Liberati</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Tetzlaff</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Altman</surname>
<given-names>DG</given-names>
</name>
<collab>PRISMA Group</collab>
</person-group>
<article-title>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</article-title>
<source/>Ann Intern Med
          <year>2009</year>
<volume>151</volume>
<fpage>264</fpage>
<lpage>269</lpage>
<pub-id pub-id-type="doi">10.7326/0003-4819-151-4-200908180-00135</pub-id>
<pub-id pub-id-type="pmid">19622511</pub-id>
</element-citation>
</ref>
<ref id="cit0022">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schardt</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Owens</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Keitz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Fontelo</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Utilization of the PICO framework to improve searching PubMed for clinical questions</article-title>
<source/>BMC Med Inform Decis Mak
          <year>2007</year>
<volume>7</volume>
<fpage>16</fpage>
<pub-id pub-id-type="doi">10.1186/1472-6947-7-16</pub-id>
<pub-id pub-id-type="pmid">17573961</pub-id>
</element-citation>
</ref>
<ref id="cit0023">
<label>23</label>
<element-citation publication-type="webpage">
<person-group person-group-type="author">
<name>
<surname>Wells</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shea</surname>
<given-names>B</given-names>
</name>
<name>
<surname>O’Connell</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<source/>The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses
          <comment><ext-link ext-link-type="uri" xlink:href="http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp">http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp</ext-link>. Published 2012. Accessed December, 2018</comment>
</element-citation>
</ref>
<ref id="cit0024">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stang</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses</article-title>
<source/>Eur J Epidemiol
          <year>2010</year>
<volume>25</volume>
<fpage>603</fpage>
<lpage>605</lpage>
<pub-id pub-id-type="doi">10.1007/s10654-010-9491-z</pub-id>
<pub-id pub-id-type="pmid">20652370</pub-id>
</element-citation>
</ref>
<ref id="cit0025">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Modesti</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Reboldi</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cappuccio</surname>
<given-names>FP</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis</article-title>
<source/>PLoS One
          <year>2016</year>
<volume>11</volume>
<fpage>e0147601</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0147601</pub-id>
<pub-id pub-id-type="pmid">26808317</pub-id>
</element-citation>
</ref>
<ref id="cit0026">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>A meta-analysis of maternal smoking during pregnancy and autism spectrum disorder risk in offspring</article-title>
<source/>Int J Environ Res Public Health
          <year>2015</year>
<volume>12</volume>
<fpage>10418</fpage>
<lpage>10431</lpage>
<pub-id pub-id-type="doi">10.3390/ijerph120910418</pub-id>
<pub-id pub-id-type="pmid">26343689</pub-id>
</element-citation>
</ref>
<ref id="cit0027">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Borenstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hedges</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Rothstein</surname>
<given-names>HR</given-names>
</name>
</person-group>
<article-title>A basic introduction to fixed-effect and random-effects models for meta-analysis</article-title>
<source/>Res Synth Methods
          <year>2010</year>
<volume>1</volume>
<fpage>97</fpage>
<lpage>111</lpage>
<pub-id pub-id-type="doi">10.1002/jrsm.12</pub-id>
<pub-id pub-id-type="pmid">26061376</pub-id>
</element-citation>
</ref>
<ref id="cit0028">
<label>28</label>
<element-citation publication-type="book">
<person-group person-group-type="author">
<collab>Review Manager [computer program]</collab>
</person-group>
<source/>Version 5.3
          <year>2014</year>
<publisher-loc>Copenhagen</publisher-loc>
<publisher-name>The Nordic Cochrane Centre, The Cochrane Collaboration</publisher-name>
</element-citation>
</ref>
<ref id="cit0029">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Islam</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>MU</given-names>
</name>
<name>
<surname>Sayeed</surname>
<given-names>MSB</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Lung cancer risk in relation to nicotinic acetylcholine receptor, <italic>CYP2A6</italic> and CYP1A1 genotypes in the Bangladeshi population</article-title>
<source/>Clin Chim Acta
          <year>2013</year>
<volume>416</volume>
<fpage>11</fpage>
<lpage>19</lpage>
<pub-id pub-id-type="doi">10.1016/j.cca.2012.11.011</pub-id>
<pub-id pub-id-type="pmid">23178447</pub-id>
</element-citation>
</ref>
<ref id="cit0030">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tamaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sugimura</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Association between cancer risk and drug-metabolizing enzyme gene (<italic>CYP2A6</italic>, CYP2A13, CYP4B1, SULT1A1, GSTM1, and GSTT1) polymorphisms in cases of lung cancer in Japan</article-title>
<source/>Drug Metab Pharmacokinet
          <year>2011</year>
<volume>26</volume>
<fpage>516</fpage>
<lpage>522</lpage>
<pub-id pub-id-type="doi">10.2133/dmpk.dmpk-11-rg-046</pub-id>
<pub-id pub-id-type="pmid">21791872</pub-id>
</element-citation>
</ref>
<ref id="cit0031">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujieda</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yamazaki</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Saito</surname>
<given-names>T</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evaluation of <italic>CYP2A6</italic> genetic polymorphisms as determinants of smoking behavior and tobacco-related lung cancer risk in male Japanese smokers</article-title>
<source/>Carcinogenesis
          <year>2004</year>
<volume>25</volume>
<fpage>2451</fpage>
<lpage>2458.</lpage>
<pub-id pub-id-type="doi">10.1093/carcin/bgh258</pub-id>
<pub-id pub-id-type="pmid">15308589</pub-id>
</element-citation>
</ref>
<ref id="cit0032">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ariyoshi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Miyamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Umetsu</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Genetic polymorphism of <italic>CYP2A6</italic> gene and tobacco-induced lung cancer risk in male smokers</article-title>
<source/>Cancer Epidemiol Biomarkers Prev
          <year>2002</year>
<volume>11</volume>
<fpage>890</fpage>
<lpage>894</lpage>
<pub-id pub-id-type="pmid">12223434</pub-id>
</element-citation>
</ref>
<ref id="cit0033">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Umetsu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dosaka-Akita</surname>
<given-names>H</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>CYP2A6</italic> gene deletion reduces susceptibility to lung cancer</article-title>
<source/>Biochem Biophys Res Commun
          <year>1999</year>
<volume>261</volume>
<fpage>658</fpage>
<lpage>660</lpage>
<pub-id pub-id-type="doi">10.1006/bbrc.1999.1089</pub-id>
<pub-id pub-id-type="pmid">10441482</pub-id>
</element-citation>
</ref>
<ref id="cit0034">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rotunno</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lubin</surname>
<given-names>JH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Phase I metabolic genes and risk of lung cancer: multiple polymorphisms and mRNA expression</article-title>
<source/>PloS One
          <year>2009</year>
<volume>4</volume>
<fpage>e5652</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0005652</pub-id>
<pub-id pub-id-type="pmid">19479063</pub-id>
</element-citation>
</ref>
<ref id="cit0035">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamataki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nunoya</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Sakai</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kushida</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Genetic polymorphism of <italic>CYP2A6</italic> in relation to cancer</article-title>
<source/>Mutat Res
          <year>1999</year>
<volume>428</volume>
<fpage>125</fpage>
<lpage>130</lpage>
<pub-id pub-id-type="doi">10.1016/s1383-5742(99)00040-x</pub-id>
<pub-id pub-id-type="pmid">10517986</pub-id>
</element-citation>
</ref>
<ref id="cit0036">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Koskela</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hakkola</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hukkanen</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Expression of CYP2A genes in human liver and extrahepatic tissues</article-title>
<source/>Biochem Pharmacol
          <year>1999</year>
<volume>57</volume>
<fpage>1407</fpage>
<lpage>1413</lpage>
<pub-id pub-id-type="doi">10.1016/s0006-2952(99)00015-5</pub-id>
<pub-id pub-id-type="pmid">10353262</pub-id>
</element-citation>
</ref>
<ref id="cit0037">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zanger</surname>
<given-names>UM</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation</article-title>
<source/>Pharmacol Ther
          <year>2013</year>
<volume>138</volume>
<fpage>103</fpage>
<lpage>141</lpage>
<pub-id pub-id-type="doi">10.1016/j.pharmthera.2012.12.007</pub-id>
<pub-id pub-id-type="pmid">23333322</pub-id>
</element-citation>
</ref>
<ref id="cit0038">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Tyndale</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>A major role for <italic>CYP2A6</italic> in nicotine C-oxidation by human liver microsomes</article-title>
<source/>J Pharmacol Exp Ther
          <year>1997</year>
<volume>282</volume>
<fpage>1608</fpage>
<lpage>1614</lpage>
<pub-id pub-id-type="pmid">9316878</pub-id>
</element-citation>
</ref>
<ref id="cit0039">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tanner</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>AZ</given-names>
</name>
<name>
<surname>Claw</surname>
<given-names>KG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Novel <italic>CYP2A6</italic> diplotypes identified through next-generation sequencing are associated with in-vitro and in-vivo nicotine metabolism</article-title>
<source/>Pharmacogenet Genomics
          <year>2018</year>
<volume>28</volume>
<fpage>7</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="doi">10.1097/fpc.0000000000000317</pub-id>
<pub-id pub-id-type="pmid">29232328</pub-id>
</element-citation>
</ref>
<ref id="cit0040">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olfson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bertelsen</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>CYP2A6</italic> metabolism in the development of smoking behaviors in young adults</article-title>
<source/>Addict Biol
          <year>2018</year>
<volume>23</volume>
<fpage>437</fpage>
<lpage>447</lpage>
<pub-id pub-id-type="doi">10.1111/adb.12477</pub-id>
<pub-id pub-id-type="pmid">28032407</pub-id>
</element-citation>
</ref>
<ref id="cit0041">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tyndale</surname>
<given-names>RF</given-names>
</name>
<name>
<surname>Sellers</surname>
<given-names>EM</given-names>
</name>
</person-group>
<article-title>Variable <italic>CYP2A6</italic>-mediated nicotine metabolism alters smoking behavior and risk</article-title>
<source/>Drug Metab Dispos
          <year>2001</year>
<volume>29</volume>
<fpage>548</fpage>
<lpage>552</lpage>
<pub-id pub-id-type="pmid">11259349</pub-id>
</element-citation>
</ref>
<ref id="cit0042">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>MA</given-names>
</name>
<etal></etal>
</person-group>
<article-title>
<italic>CYP2A6</italic>, CYP1A1, and CYP2D6 polymorphisms in lung cancer patients from Central South China</article-title>
<source/>Med Oncol
          <year>2013</year>
<volume>30</volume>
<fpage>521</fpage>
<pub-id pub-id-type="doi">10.1007/s12032-013-0521-z</pub-id>
<pub-id pub-id-type="pmid">23471717</pub-id>
</element-citation>
</ref>
<ref id="cit0043">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Khuder</surname>
<given-names>SA</given-names>
</name>
</person-group>
<article-title>Effect of cigarette smoking on major histological types of lung cancer: a meta-analysis</article-title>
<source/>Lung Cancer
          <year>2001</year>
<volume>31</volume>
<fpage>139</fpage>
<lpage>148</lpage>
<pub-id pub-id-type="doi">10.1016/s0169-5002(00)00181-1</pub-id>
<pub-id pub-id-type="pmid">11165392</pub-id>
</element-citation>
</ref>
<ref id="cit0044">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Risch</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Howe</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Jain</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Burch</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Holowaty</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>AB</given-names>
</name>
</person-group>
<article-title>Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type</article-title>
<source/>Am J Epidemiol
          <year>1993</year>
<volume>138</volume>
<fpage>281</fpage>
<lpage>293</lpage>
<pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a116857</pub-id>
<pub-id pub-id-type="pmid">8395141</pub-id>
</element-citation>
</ref>
<ref id="cit0045">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbone</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bovenzi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cavallieri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stanta</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Cigarette smoking and histologic type of lung cancer in men</article-title>
<source/>Chest
          <year>1997</year>
<volume>112</volume>
<fpage>1474</fpage>
<lpage>1479</lpage>
<pub-id pub-id-type="doi">10.1378/chest.112.6.1474</pub-id>
<pub-id pub-id-type="pmid">9404741</pub-id>
</element-citation>
</ref>
<ref id="cit0046">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Peters</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kromhout</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Olsson</surname>
<given-names>AC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Occupational exposure to organic dust increases lung cancer risk in the general population</article-title>
<source/>Thorax
          <year>2012</year>
<volume>67</volume>
<fpage>111</fpage>
<lpage>116</lpage>
<pub-id pub-id-type="doi">10.1136/thoraxjnl-2011-200716</pub-id>
<pub-id pub-id-type="pmid">21856697</pub-id>
</element-citation>
</ref>
<ref id="cit0047">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pelucchi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pira</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Piolatto</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Coggiola</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carta</surname>
<given-names>P</given-names>
</name>
<name>
<surname>La Vecchia</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Occupational silica exposure and lung cancer risk: a review of epidemiological studies 1996–2005</article-title>
<source/>Ann Oncol
          <year>2006</year>
<volume>17</volume>
<fpage>1039</fpage>
<lpage>1050</lpage>
<pub-id pub-id-type="doi">10.1093/annonc/mdj125</pub-id>
<pub-id pub-id-type="pmid">16403810</pub-id>
</element-citation>
</ref>
<ref id="cit0048">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Klassen</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Pankiewicz</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kabbe</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hayes</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Curriero</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>The association of neighborhood-level social class and tobacco consumption with adverse lung cancer characteristics in Maryland</article-title>
<source/>Tob Induc Dis
          <year>2019</year>
<volume>17</volume>
<issue>January</issue>
<pub-id pub-id-type="doi">10.18332/tid/100525</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>